Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
07:19am, Thursday, 20'th Mar 2025
Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024,
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
09:53am, Wednesday, 19'th Mar 2025
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demons
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock?
08:46am, Tuesday, 18'th Mar 2025
When it comes to clinical weight-loss treatments, GLP-1 therapies have taken the medical sector by storm. What started as off-label use by celebrities and social media influencers for cutting weight b
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
06:51pm, Thursday, 13'th Mar 2025
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
Viking Therapeutics: No Buyout Needed Now
01:12pm, Thursday, 13'th Mar 2025
Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs. The biotech announced a production deal with CordenPharma, signaling confidence
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
11:26am, Thursday, 13'th Mar 2025
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
12:08pm, Wednesday, 12'th Mar 2025
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22
Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.
11:54am, Wednesday, 12'th Mar 2025
Viking has found a manufacturing partner, removing a key overhang on the stock.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
09:20am, Wednesday, 12'th Mar 2025
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Viking Therapeutics Is Ready For A Standalone Future
07:07am, Wednesday, 12'th Mar 2025
Viking Therapeutics announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. The deal covers a substantial supply of both the subcutaneous and oral VK2735
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)
12:43pm, Tuesday, 11'th Mar 2025
The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.
10:16am, Tuesday, 11'th Mar 2025
Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Man
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
07:03am, Tuesday, 11'th Mar 2025
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply
Viking Therapeutics: Signs Of Insufficient Differentiation In Obesity Treatment (Rating Downgrade)
11:18pm, Monday, 10'th Mar 2025
Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 agonis
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
06:50pm, Friday, 07'th Mar 2025
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.
